Last update:
The security valuation IPO involves a net offer for sale of 19,189,330 equity shares of Rs 846.25 crore (at the above price band
Security Evaluation IPO Size: Check price band, listing date.
Sarksha Diagnostics Limited, a leading integrated diagnostics chain, is all set to launch its Rs 846 crore initial public offering (IPO) on November 29, 2024. The Kolkata-based company, known for its comprehensive pathology, radiology, and medical consultancy services, operates a vast network across eastern India and aims to list its equity shares on BSE and NSE. Through this public offering.
Protection Diagnostics IPO size
Price band and IPO details
Tahakuz Diagnostics Ltd has announced a price band of Rs 420 to Rs 441 per share for its Rs 846 crore initial public offering (IPO).
IPO Dates: Public subscription opens on November 29 and closes on December 3, 2024.
Anchor Investor Bid: Due November 28, 2024.
Structure of the offer
The IPO involves a net offer for sale (OFS) of 19,189,330 equity shares valued at Rs 846.25 crore (at the upper price band).
Sale of shares by promoters and shareholders:
Promoters: Somnath Chatterjee, Ritu Mittal, and Satish Kumar Verma.
Investors: OrbiMed Asia II Mauritius Ltd, Munna Lal Kejriwal, and Santosh Kumar Kejriwal.
No fresh issues: All proceeds from the IPO will go to the selling shareholders.
Purpose of IPO
Listing of Equity Shares in Stock Exchange.
– Facilitation of OFS by existing shareholders.
Protection Valuation IPO Market Cap
Market capitalization
At the upper end of the price band, the company has a market value of around Rs 2,300 crore.
Business overview
Suraksha Diagnostic Ltd provides one-stop integrated solutions for pathology, radiology testing, and clinical consultation.
network:
- Central Reference Laboratory (Flagship).
- 8 Satellite Laboratories.
- 194 customer touch points, including:
- 48 diagnostic centers.
- 146 sample collection centers (mainly franchised).Geographical Presence: Works in West Bengal, Bihar, Assam and Meghalaya till 31 March 2024.Operational Performance: In FY 2024, 5.98 million tests were conducted on 1.14 million patients.
IPO allocation
- 50%: Reserved for Qualified Institutional Buyers (QIBs).
- 35%: Reserved for retail investors.
- 10%: Reserved for Non-Institutional Investors (NIIs).
Book Running Lead Manager:
- ICICI SECURITIES LIMITED
- NOAMA WEALTH MANAGEMENT LIMITED
- SBI Capital Markets Ltd
Date of Listing: The equity shares are expected to be listed on BSE and NSE on December 6, 2024.